Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGD | P52209 | 4/20 | 0.43 |
| ▸ | PGK1 | P00558 | 1/20 | 0.42 |
| ▸ | PGK2 | P07205 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MPI | P34949 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.31 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.31 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.31 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.31 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.31 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.31 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9736405 | 1.00 | PGD (0.43) | PGDPGK1PGK2CYP2C9TSHR | |
| SCHEMBL37330 | 1.00 | PGD (0.43) | PGDPGK1PGK2CYP2C9TSHR | |
| SCHEMBL1526127 | 0.95 | PGD (0.42) | PGDPGK1PGK2CYP2C9TSHR | |
| SCHEMBL372294 | 0.90 | PGD (0.46) | PGDPGK1PGK2CYP2C9TSHR | |
| SCHEMBL9739404 | 0.85 | PGD (0.42) | PGDPGK1PGK2CYP2C9TSHR | |
| SCHEMBL9737463 | 0.85 | PGD (0.42) | PGDPGK1PGK2CYP2C9TSHR | |
| SCHEMBL9736618 | 0.85 | PGD (0.42) | PGDPGK1PGK2CYP2C9TSHR | |
| SCHEMBL9738891 | 0.85 | PGD (0.42) | PGDPGK1PGK2CYP2C9TSHR | |
| SCHEMBL7803701 | 0.84 | CYP2C9 (0.44) | PGDCYP2C9TSHRPTPN1 | |
| SCHEMBL939123 | 0.81 | PGD (0.56) | PGDPGK1PGK2CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020159976-A1 | Lactobacillus rhamnosus polynucleotides, polypeptides and methods for using them | VIALACTIA BIOSCIENCE (NZ) LIMITED (NZ) | 2002-10-31 | — | — | US | claimed |
| WO-2020067788-A1 | NOVEL FRUCTOSE-4-EPIMERASE AND TAGATOSE PRODUCTION METHOD USING SAME | 씨제이제일제당 (주) | 2020-04-02 | — | — | WO | disclosed |
| WO-2020067781-A1 | NOVEL FRUCTOSE-4-EPIMERASE AND TAGATOSE PRODUCTION METHOD USING SAME | 씨제이제일제당 (주) | 2020-04-02 | — | — | WO | disclosed |
| WO-2020067786-A1 | NOVEL FRUCTOSE-4-EPIMERASE AND TAGATOSE PRODUCTION METHOD USING SAME | 씨제이제일제당 (주) | 2020-04-02 | — | — | WO | disclosed |
| US-20180298064-A1 | PROTEINS AND NUCLEIC ACIDS FROM MENINGITIS/SEPSIS-ASSOCIATED ESCHERICHIA COLI | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2018-10-18 | — | — | US | disclosed |
| US-10035826-B2 | Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2018-07-31 | — | — | US | disclosed |
| US-20160244489-A1 | PROTEINS AND NUCLEIC ACIDS FROM MENINGITIS/SEPSIS-ASSOCIATED ESCHERICHIA COLI | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2016-08-25 | — | — | US | disclosed |
| US-9334313-B2 | Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2016-05-10 | — | — | US | disclosed |
| US-20140356389-A1 | PROTEINS AND NUCLEIC ACIDS FROM MENINGITIS/SEPSIS-ASSOCIATED ESCHERICHIA COLI | J. CRAIG VENTER INSTITUTE, INC. (US) | 2014-12-04 | — | — | US | disclosed |
| US-8758764-B2 | Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli | NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT) | 2014-06-24 | — | — | US | disclosed |
| US-20080193470-A1 | For immunizing against MNEC infections | GLAXOSMITHKLINE VACCINES S.R.L. (BE) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140356389-A1 | PROTEINS AND NUCLEIC ACIDS FROM MENINGITIS/SEPSIS-ASSOCIATED ESCHERICHIA COLI | SNRPE, NSUN3, DNASE1 | PGD 3361/4885PGK1 2541/4885PGK2 2936/4885 |
| US-10035826-B2 | Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli | SNRPE, NSUN3, DNASE1 | PGD 3397/4885PGK1 2535/4885PGK2 2949/4885 |
| US-20160244489-A1 | PROTEINS AND NUCLEIC ACIDS FROM MENINGITIS/SEPSIS-ASSOCIATED ESCHERICHIA COLI | SNRPE, NSUN3, DNASE1 | PGD 3361/4885PGK1 2541/4885PGK2 2936/4885 |
| US-20080193470-A1 | For immunizing against MNEC infections | MLEC, GMFG, MYD88 | PGD 4048/4885PGK1 3610/4885PGK2 3906/4885 |
| US-20180298064-A1 | PROTEINS AND NUCLEIC ACIDS FROM MENINGITIS/SEPSIS-ASSOCIATED ESCHERICHIA COLI | SNRPE, NSUN3, DNASE1 | PGD 3361/4885PGK1 2541/4885PGK2 2936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.